Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2020-10-07

AUTHORS

Chung-Han Lee, Robert J. Motzer, Hilary Glen, M. D. Michaelson, James Larkin, Yukinori Minoshima, Michio Kanekiyo, Hiroki Ikezawa, Pallavi Sachdev, Corina E. Dutcus, Yasuhiro Funahashi, Martin H. Voss

ABSTRACT

BackgroundNo biomarkers have been established to predict treatment efficacy in renal cell carcinoma (RCC). In an exploratory retrospective analysis of a Phase 2 study, we constructed composite biomarker scores (CBSs) to predict progression-free survival (PFS) and overall survival (OS) in patients with metastatic RCC randomised to receive lenvatinib-plus-everolimus.MethodsOf 40 biomarkers tested, the 5 most strongly associated with PFS (HGF, MIG, IL-18BP, IL-18, ANG-2) or OS (TIMP-1, M-CSF, IL-18BP, ANG-2, VEGF) were used to make a 5-factor PFS-CBS or OS-CBS, respectively. A 2-factor CBS was generated with biomarkers common to PFS-CBS and OS-CBS. Patients were divided into groups accordingly (5-factor-CBS high: 3−5, CBS-low: 0–2; 2-factor-CBS high: 1–2, CBS-low: 0).ResultsPFS/OS with lenvatinib-plus-everolimus were significantly longer in the 5-factor CBS-high group versus the CBS-low group (P = 0.0022/P < 0.0001, respectively). In the CBS-high group, PFS/OS were significantly longer with lenvatinib-plus-everolimus versus everolimus (P < 0.001/P = 0.0079, respectively); PFS was also significantly longer with lenvatinib-plus-everolimus versus lenvatinib (P = 0.0046). The 5-factor-CBS had a predictive role in PFS and OS after multivariate analysis. Similar trends were observed with the 2-factor-CBS for PFS (i.e., lenvatinib-plus-everolimus versus everolimus).ConclusionsThe 5-factor CBS may identify patients with metastatic RCC who would benefit from lenvatinib-plus-everolimus versus everolimus; additional validation is required.Clinical trial registrationThe clinical trial registration number is NCT01136733. More... »

PAGES

237-246

References to SciGraph publications

  • 2016-09-20. TIMP1 is a prognostic marker for the progression and metastasis of colon cancer through FAK-PI3K/AKT and MAPK pathway in JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
  • 2007-07-02. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2016-02-23. Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma in BRITISH JOURNAL OF CANCER
  • 2006-05-04. Combination of MIG (CXCL9) chemokine gene therapy with low-dose cisplatin improves therapeutic efficacy against murine carcinoma in GENE THERAPY
  • 2014-02-02. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing in NATURE GENETICS
  • 2009-12-15. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors in BRITISH JOURNAL OF CANCER
  • 2014-08-07. Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2013-11-13. Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2014-09-06. Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage in VASCULAR CELL
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1038/s41416-020-01092-0

    DOI

    http://dx.doi.org/10.1038/s41416-020-01092-0

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1131472729

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/33024271


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Oncology and Carcinogenesis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Adult", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antineoplastic Combined Chemotherapy Protocols", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Biomarkers, Tumor", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Carcinoma, Renal Cell", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Everolimus", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Female", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Kidney Neoplasms", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Male", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Middle Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Phenylurea Compounds", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Progression-Free Survival", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Quinolines", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Treatment Outcome", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA", 
              "id": "http://www.grid.ac/institutes/grid.51462.34", 
              "name": [
                "Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Lee", 
            "givenName": "Chung-Han", 
            "id": "sg:person.0702522471.03", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0702522471.03"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA", 
              "id": "http://www.grid.ac/institutes/grid.51462.34", 
              "name": [
                "Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Motzer", 
            "givenName": "Robert J.", 
            "id": "sg:person.01234500340.18", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01234500340.18"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Medical Oncology, Beatson West of Scotland Cancer Center, Glasgow, UK", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Medical Oncology, Beatson West of Scotland Cancer Center, Glasgow, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Glen", 
            "givenName": "Hilary", 
            "id": "sg:person.01213406417.41", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01213406417.41"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Massachusetts General Hospital Cancer Center, Boston, MA, USA", 
              "id": "http://www.grid.ac/institutes/grid.32224.35", 
              "name": [
                "Massachusetts General Hospital Cancer Center, Boston, MA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Michaelson", 
            "givenName": "M. D.", 
            "id": "sg:person.0742055352.47", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0742055352.47"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Medical Oncology, Royal Marsden NHS Foundation Trust, London, UK", 
              "id": "http://www.grid.ac/institutes/grid.5072.0", 
              "name": [
                "Department of Medical Oncology, Royal Marsden NHS Foundation Trust, London, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Larkin", 
            "givenName": "James", 
            "id": "sg:person.01255356274.07", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01255356274.07"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Eisai Co., Ltd, Ibaraki, Japan", 
              "id": "http://www.grid.ac/institutes/grid.418765.9", 
              "name": [
                "Eisai Co., Ltd, Ibaraki, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Minoshima", 
            "givenName": "Yukinori", 
            "id": "sg:person.0667363520.21", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0667363520.21"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Eisai Inc., Woodcliff Lake, NJ, USA", 
              "id": "http://www.grid.ac/institutes/grid.418767.b", 
              "name": [
                "Eisai Inc., Woodcliff Lake, NJ, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Kanekiyo", 
            "givenName": "Michio", 
            "id": "sg:person.012346136554.35", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012346136554.35"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Eisai, Co., Ltd, Tokyo, Japan", 
              "id": "http://www.grid.ac/institutes/grid.418765.9", 
              "name": [
                "Eisai, Co., Ltd, Tokyo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Ikezawa", 
            "givenName": "Hiroki", 
            "id": "sg:person.010610671627.59", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010610671627.59"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Eisai Inc., Woodcliff Lake, NJ, USA", 
              "id": "http://www.grid.ac/institutes/grid.418767.b", 
              "name": [
                "Eisai Inc., Woodcliff Lake, NJ, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Sachdev", 
            "givenName": "Pallavi", 
            "id": "sg:person.0637142015.19", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0637142015.19"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Eisai Inc., Woodcliff Lake, NJ, USA", 
              "id": "http://www.grid.ac/institutes/grid.418767.b", 
              "name": [
                "Eisai Inc., Woodcliff Lake, NJ, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Dutcus", 
            "givenName": "Corina E.", 
            "id": "sg:person.01050166607.38", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01050166607.38"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Eisai Co., Ltd, Ibaraki, Japan", 
              "id": "http://www.grid.ac/institutes/grid.418765.9", 
              "name": [
                "Eisai Co., Ltd, Ibaraki, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Funahashi", 
            "givenName": "Yasuhiro", 
            "id": "sg:person.01327037724.48", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01327037724.48"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA", 
              "id": "http://www.grid.ac/institutes/grid.51462.34", 
              "name": [
                "Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Voss", 
            "givenName": "Martin H.", 
            "id": "sg:person.0577111044.36", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0577111044.36"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1186/2045-824x-6-18", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1021771246", 
              "https://doi.org/10.1186/2045-824x-6-18"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ng.2891", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1022690077", 
              "https://doi.org/10.1038/ng.2891"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s13046-016-0427-7", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1019155476", 
              "https://doi.org/10.1186/s13046-016-0427-7"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00280-013-2333-4", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1044006130", 
              "https://doi.org/10.1007/s00280-013-2333-4"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00280-014-2539-0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1012987255", 
              "https://doi.org/10.1007/s00280-014-2539-0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/bjc.2016.21", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1040730926", 
              "https://doi.org/10.1038/bjc.2016.21"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.gt.3302756", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1017810235", 
              "https://doi.org/10.1038/sj.gt.3302756"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.bjc.6605483", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1007615167", 
              "https://doi.org/10.1038/sj.bjc.6605483"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/1479-5876-5-32", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1001875982", 
              "https://doi.org/10.1186/1479-5876-5-32"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2020-10-07", 
        "datePublishedReg": "2020-10-07", 
        "description": "BackgroundNo biomarkers have been established to predict treatment efficacy in renal cell carcinoma (RCC). In an exploratory retrospective analysis of a Phase 2 study, we constructed composite biomarker scores (CBSs) to predict progression-free survival (PFS) and overall survival (OS) in patients with metastatic RCC randomised to receive lenvatinib-plus-everolimus.MethodsOf 40 biomarkers tested, the 5 most strongly associated with PFS (HGF, MIG, IL-18BP, IL-18, ANG-2) or OS (TIMP-1, M-CSF, IL-18BP, ANG-2, VEGF) were used to make a 5-factor PFS-CBS or OS-CBS, respectively. A 2-factor CBS was generated with biomarkers common to PFS-CBS and OS-CBS. Patients were divided into groups accordingly (5-factor-CBS high: 3\u22125, CBS-low: 0\u20132; 2-factor-CBS high: 1\u20132, CBS-low: 0).ResultsPFS/OS with lenvatinib-plus-everolimus were significantly longer in the 5-factor CBS-high group versus the CBS-low group (P\u2009=\u20090.0022/P\u2009<\u20090.0001, respectively). In the CBS-high group, PFS/OS were significantly longer with lenvatinib-plus-everolimus versus everolimus (P\u2009<\u20090.001/P\u2009=\u20090.0079, respectively); PFS was also significantly longer with lenvatinib-plus-everolimus versus lenvatinib (P\u2009=\u20090.0046). The 5-factor-CBS had a predictive role in PFS and OS after multivariate analysis. Similar trends were observed with the 2-factor-CBS for PFS (i.e., lenvatinib-plus-everolimus versus everolimus).ConclusionsThe 5-factor CBS may identify patients with metastatic RCC who would benefit from lenvatinib-plus-everolimus versus everolimus; additional validation is required.Clinical trial registrationThe clinical trial registration number is NCT01136733.", 
        "genre": "article", 
        "id": "sg:pub.10.1038/s41416-020-01092-0", 
        "isAccessibleForFree": true, 
        "isFundedItemOf": [
          {
            "id": "sg:grant.2438793", 
            "type": "MonetaryGrant"
          }
        ], 
        "isPartOf": [
          {
            "id": "sg:journal.1017082", 
            "issn": [
              "0007-0920", 
              "1532-1827"
            ], 
            "name": "British Journal of Cancer", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "1", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "124"
          }
        ], 
        "keywords": [
          "composite biomarker score", 
          "progression-free survival", 
          "metastatic renal cell carcinoma", 
          "renal cell carcinoma", 
          "overall survival", 
          "cell carcinoma", 
          "PFS/overall survival", 
          "clinical trial registration number", 
          "exploratory retrospective analysis", 
          "phase 2 study", 
          "phase 2 trial", 
          "TRIAL REGISTRATION NUMBER", 
          "serum biomarker analysis", 
          "retrospective analysis", 
          "biomarker score", 
          "lenvatinib", 
          "everolimus", 
          "treatment efficacy", 
          "registration number", 
          "patients", 
          "multivariate analysis", 
          "predictive role", 
          "high group", 
          "biomarkers", 
          "carcinoma", 
          "biomarker analysis", 
          "survival", 
          "group", 
          "trials", 
          "additional validation", 
          "efficacy", 
          "scores", 
          "similar trend", 
          "ConclusionsThe", 
          "analysis", 
          "study", 
          "role", 
          "number", 
          "validation", 
          "trends"
        ], 
        "name": "Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma", 
        "pagination": "237-246", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1131472729"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1038/s41416-020-01092-0"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "33024271"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1038/s41416-020-01092-0", 
          "https://app.dimensions.ai/details/publication/pub.1131472729"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-09-02T16:05", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_843.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1038/s41416-020-01092-0"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/s41416-020-01092-0'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/s41416-020-01092-0'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/s41416-020-01092-0'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/s41416-020-01092-0'


     

    This table displays all metadata directly associated to this object as RDF triples.

    293 TRIPLES      21 PREDICATES      89 URIs      72 LITERALS      22 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1038/s41416-020-01092-0 schema:about N3773a26c57374b8f8feec109ab445976
    2 N3e29163746114d1ea242224b50d35ad7
    3 N3f711cabf3ff426995b16b1f77c8fc7d
    4 N443b46e28dca4c3091e08e2968281d88
    5 N46946966b19b432db07a79ac3437ef3d
    6 N6cb3a24170034c2481faa0f463383500
    7 N6f1eb5def41d4c4c8617dd0275e66f6a
    8 N7b8896d1ab374c28909d96b8ba0cdf4d
    9 N818d9e2675d743f1b16ee81eaf64a08f
    10 Na427ac020f224b9a84b286d3d410922e
    11 Nb6cb6cc813834c1f9f85a7a6b84954d4
    12 Nc6891f8a01e445d5b03d26da71ffc8cc
    13 Nc99f1ce81e94473187b90769af78fd84
    14 Ndb97a3528ebf447ab20d57c33e89bc8c
    15 Necd327cf72ea48378969e51d36d4b86c
    16 anzsrc-for:11
    17 anzsrc-for:1112
    18 schema:author N85b3cea5512042408a4e04d1a3b430b2
    19 schema:citation sg:pub.10.1007/s00280-013-2333-4
    20 sg:pub.10.1007/s00280-014-2539-0
    21 sg:pub.10.1038/bjc.2016.21
    22 sg:pub.10.1038/ng.2891
    23 sg:pub.10.1038/sj.bjc.6605483
    24 sg:pub.10.1038/sj.gt.3302756
    25 sg:pub.10.1186/1479-5876-5-32
    26 sg:pub.10.1186/2045-824x-6-18
    27 sg:pub.10.1186/s13046-016-0427-7
    28 schema:datePublished 2020-10-07
    29 schema:datePublishedReg 2020-10-07
    30 schema:description BackgroundNo biomarkers have been established to predict treatment efficacy in renal cell carcinoma (RCC). In an exploratory retrospective analysis of a Phase 2 study, we constructed composite biomarker scores (CBSs) to predict progression-free survival (PFS) and overall survival (OS) in patients with metastatic RCC randomised to receive lenvatinib-plus-everolimus.MethodsOf 40 biomarkers tested, the 5 most strongly associated with PFS (HGF, MIG, IL-18BP, IL-18, ANG-2) or OS (TIMP-1, M-CSF, IL-18BP, ANG-2, VEGF) were used to make a 5-factor PFS-CBS or OS-CBS, respectively. A 2-factor CBS was generated with biomarkers common to PFS-CBS and OS-CBS. Patients were divided into groups accordingly (5-factor-CBS high: 3−5, CBS-low: 0–2; 2-factor-CBS high: 1–2, CBS-low: 0).ResultsPFS/OS with lenvatinib-plus-everolimus were significantly longer in the 5-factor CBS-high group versus the CBS-low group (P = 0.0022/P < 0.0001, respectively). In the CBS-high group, PFS/OS were significantly longer with lenvatinib-plus-everolimus versus everolimus (P < 0.001/P = 0.0079, respectively); PFS was also significantly longer with lenvatinib-plus-everolimus versus lenvatinib (P = 0.0046). The 5-factor-CBS had a predictive role in PFS and OS after multivariate analysis. Similar trends were observed with the 2-factor-CBS for PFS (i.e., lenvatinib-plus-everolimus versus everolimus).ConclusionsThe 5-factor CBS may identify patients with metastatic RCC who would benefit from lenvatinib-plus-everolimus versus everolimus; additional validation is required.Clinical trial registrationThe clinical trial registration number is NCT01136733.
    31 schema:genre article
    32 schema:isAccessibleForFree true
    33 schema:isPartOf N30a72a5701ad4988b50992225bdbcc8a
    34 Na715fa264e024a9b8c70cfe29acd9e40
    35 sg:journal.1017082
    36 schema:keywords ConclusionsThe
    37 PFS/overall survival
    38 TRIAL REGISTRATION NUMBER
    39 additional validation
    40 analysis
    41 biomarker analysis
    42 biomarker score
    43 biomarkers
    44 carcinoma
    45 cell carcinoma
    46 clinical trial registration number
    47 composite biomarker score
    48 efficacy
    49 everolimus
    50 exploratory retrospective analysis
    51 group
    52 high group
    53 lenvatinib
    54 metastatic renal cell carcinoma
    55 multivariate analysis
    56 number
    57 overall survival
    58 patients
    59 phase 2 study
    60 phase 2 trial
    61 predictive role
    62 progression-free survival
    63 registration number
    64 renal cell carcinoma
    65 retrospective analysis
    66 role
    67 scores
    68 serum biomarker analysis
    69 similar trend
    70 study
    71 survival
    72 treatment efficacy
    73 trends
    74 trials
    75 validation
    76 schema:name Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma
    77 schema:pagination 237-246
    78 schema:productId N0ffc2830cbe74d4da2d9ed554341fa7a
    79 N836c667945c14ccfbc493b9cfd8a32b6
    80 N85a4afd8b6934ff5940d9bc975bf1249
    81 schema:sameAs https://app.dimensions.ai/details/publication/pub.1131472729
    82 https://doi.org/10.1038/s41416-020-01092-0
    83 schema:sdDatePublished 2022-09-02T16:05
    84 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    85 schema:sdPublisher N7af3d2703c064221a8e3c628a76125c5
    86 schema:url https://doi.org/10.1038/s41416-020-01092-0
    87 sgo:license sg:explorer/license/
    88 sgo:sdDataset articles
    89 rdf:type schema:ScholarlyArticle
    90 N0ffc2830cbe74d4da2d9ed554341fa7a schema:name pubmed_id
    91 schema:value 33024271
    92 rdf:type schema:PropertyValue
    93 N2558f635d3c94e7a9c30ee2d36821568 rdf:first sg:person.012346136554.35
    94 rdf:rest Ncea459c2de484112ab4f1bc007bf41b4
    95 N2736ce0b39e147008edba5484d3b4063 rdf:first sg:person.0637142015.19
    96 rdf:rest N3c65af764105490bb6639f31cef8e259
    97 N30a72a5701ad4988b50992225bdbcc8a schema:issueNumber 1
    98 rdf:type schema:PublicationIssue
    99 N33cf09c43cdd40c8a107aba43b4c8e5b rdf:first sg:person.0577111044.36
    100 rdf:rest rdf:nil
    101 N3773a26c57374b8f8feec109ab445976 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    102 schema:name Middle Aged
    103 rdf:type schema:DefinedTerm
    104 N3c65af764105490bb6639f31cef8e259 rdf:first sg:person.01050166607.38
    105 rdf:rest N55521e2cdc6e4599baf993ba8c55a3ee
    106 N3d567c6c704e466ab5e6d631c4e4dca0 rdf:first sg:person.01213406417.41
    107 rdf:rest N4a32cff6aaa24d829cb861bf38a5c1c9
    108 N3e29163746114d1ea242224b50d35ad7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    109 schema:name Carcinoma, Renal Cell
    110 rdf:type schema:DefinedTerm
    111 N3f711cabf3ff426995b16b1f77c8fc7d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    112 schema:name Everolimus
    113 rdf:type schema:DefinedTerm
    114 N443b46e28dca4c3091e08e2968281d88 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    115 schema:name Phenylurea Compounds
    116 rdf:type schema:DefinedTerm
    117 N46946966b19b432db07a79ac3437ef3d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    118 schema:name Male
    119 rdf:type schema:DefinedTerm
    120 N4a32cff6aaa24d829cb861bf38a5c1c9 rdf:first sg:person.0742055352.47
    121 rdf:rest Nbc0ea39d4d514449a2880d77336a5d49
    122 N55521e2cdc6e4599baf993ba8c55a3ee rdf:first sg:person.01327037724.48
    123 rdf:rest N33cf09c43cdd40c8a107aba43b4c8e5b
    124 N6cb3a24170034c2481faa0f463383500 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    125 schema:name Kidney Neoplasms
    126 rdf:type schema:DefinedTerm
    127 N6f1eb5def41d4c4c8617dd0275e66f6a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    128 schema:name Antineoplastic Combined Chemotherapy Protocols
    129 rdf:type schema:DefinedTerm
    130 N753b220df90540c38c1c9707d8344cfc rdf:first sg:person.01234500340.18
    131 rdf:rest N3d567c6c704e466ab5e6d631c4e4dca0
    132 N7af3d2703c064221a8e3c628a76125c5 schema:name Springer Nature - SN SciGraph project
    133 rdf:type schema:Organization
    134 N7b8896d1ab374c28909d96b8ba0cdf4d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    135 schema:name Adult
    136 rdf:type schema:DefinedTerm
    137 N818d9e2675d743f1b16ee81eaf64a08f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    138 schema:name Biomarkers, Tumor
    139 rdf:type schema:DefinedTerm
    140 N836c667945c14ccfbc493b9cfd8a32b6 schema:name doi
    141 schema:value 10.1038/s41416-020-01092-0
    142 rdf:type schema:PropertyValue
    143 N85a4afd8b6934ff5940d9bc975bf1249 schema:name dimensions_id
    144 schema:value pub.1131472729
    145 rdf:type schema:PropertyValue
    146 N85b3cea5512042408a4e04d1a3b430b2 rdf:first sg:person.0702522471.03
    147 rdf:rest N753b220df90540c38c1c9707d8344cfc
    148 Na427ac020f224b9a84b286d3d410922e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    149 schema:name Quinolines
    150 rdf:type schema:DefinedTerm
    151 Na715fa264e024a9b8c70cfe29acd9e40 schema:volumeNumber 124
    152 rdf:type schema:PublicationVolume
    153 Nb6cb6cc813834c1f9f85a7a6b84954d4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    154 schema:name Humans
    155 rdf:type schema:DefinedTerm
    156 Nbc0ea39d4d514449a2880d77336a5d49 rdf:first sg:person.01255356274.07
    157 rdf:rest Nbd9db1f3fa0a4607930d082376112c24
    158 Nbd9db1f3fa0a4607930d082376112c24 rdf:first sg:person.0667363520.21
    159 rdf:rest N2558f635d3c94e7a9c30ee2d36821568
    160 Nc6891f8a01e445d5b03d26da71ffc8cc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    161 schema:name Treatment Outcome
    162 rdf:type schema:DefinedTerm
    163 Nc99f1ce81e94473187b90769af78fd84 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    164 schema:name Female
    165 rdf:type schema:DefinedTerm
    166 Ncea459c2de484112ab4f1bc007bf41b4 rdf:first sg:person.010610671627.59
    167 rdf:rest N2736ce0b39e147008edba5484d3b4063
    168 Ndb97a3528ebf447ab20d57c33e89bc8c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    169 schema:name Aged
    170 rdf:type schema:DefinedTerm
    171 Necd327cf72ea48378969e51d36d4b86c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    172 schema:name Progression-Free Survival
    173 rdf:type schema:DefinedTerm
    174 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    175 schema:name Medical and Health Sciences
    176 rdf:type schema:DefinedTerm
    177 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
    178 schema:name Oncology and Carcinogenesis
    179 rdf:type schema:DefinedTerm
    180 sg:grant.2438793 http://pending.schema.org/fundedItem sg:pub.10.1038/s41416-020-01092-0
    181 rdf:type schema:MonetaryGrant
    182 sg:journal.1017082 schema:issn 0007-0920
    183 1532-1827
    184 schema:name British Journal of Cancer
    185 schema:publisher Springer Nature
    186 rdf:type schema:Periodical
    187 sg:person.01050166607.38 schema:affiliation grid-institutes:grid.418767.b
    188 schema:familyName Dutcus
    189 schema:givenName Corina E.
    190 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01050166607.38
    191 rdf:type schema:Person
    192 sg:person.010610671627.59 schema:affiliation grid-institutes:grid.418765.9
    193 schema:familyName Ikezawa
    194 schema:givenName Hiroki
    195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010610671627.59
    196 rdf:type schema:Person
    197 sg:person.01213406417.41 schema:affiliation grid-institutes:None
    198 schema:familyName Glen
    199 schema:givenName Hilary
    200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01213406417.41
    201 rdf:type schema:Person
    202 sg:person.01234500340.18 schema:affiliation grid-institutes:grid.51462.34
    203 schema:familyName Motzer
    204 schema:givenName Robert J.
    205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01234500340.18
    206 rdf:type schema:Person
    207 sg:person.012346136554.35 schema:affiliation grid-institutes:grid.418767.b
    208 schema:familyName Kanekiyo
    209 schema:givenName Michio
    210 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012346136554.35
    211 rdf:type schema:Person
    212 sg:person.01255356274.07 schema:affiliation grid-institutes:grid.5072.0
    213 schema:familyName Larkin
    214 schema:givenName James
    215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01255356274.07
    216 rdf:type schema:Person
    217 sg:person.01327037724.48 schema:affiliation grid-institutes:grid.418765.9
    218 schema:familyName Funahashi
    219 schema:givenName Yasuhiro
    220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01327037724.48
    221 rdf:type schema:Person
    222 sg:person.0577111044.36 schema:affiliation grid-institutes:grid.51462.34
    223 schema:familyName Voss
    224 schema:givenName Martin H.
    225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0577111044.36
    226 rdf:type schema:Person
    227 sg:person.0637142015.19 schema:affiliation grid-institutes:grid.418767.b
    228 schema:familyName Sachdev
    229 schema:givenName Pallavi
    230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0637142015.19
    231 rdf:type schema:Person
    232 sg:person.0667363520.21 schema:affiliation grid-institutes:grid.418765.9
    233 schema:familyName Minoshima
    234 schema:givenName Yukinori
    235 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0667363520.21
    236 rdf:type schema:Person
    237 sg:person.0702522471.03 schema:affiliation grid-institutes:grid.51462.34
    238 schema:familyName Lee
    239 schema:givenName Chung-Han
    240 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0702522471.03
    241 rdf:type schema:Person
    242 sg:person.0742055352.47 schema:affiliation grid-institutes:grid.32224.35
    243 schema:familyName Michaelson
    244 schema:givenName M. D.
    245 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0742055352.47
    246 rdf:type schema:Person
    247 sg:pub.10.1007/s00280-013-2333-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044006130
    248 https://doi.org/10.1007/s00280-013-2333-4
    249 rdf:type schema:CreativeWork
    250 sg:pub.10.1007/s00280-014-2539-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012987255
    251 https://doi.org/10.1007/s00280-014-2539-0
    252 rdf:type schema:CreativeWork
    253 sg:pub.10.1038/bjc.2016.21 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040730926
    254 https://doi.org/10.1038/bjc.2016.21
    255 rdf:type schema:CreativeWork
    256 sg:pub.10.1038/ng.2891 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022690077
    257 https://doi.org/10.1038/ng.2891
    258 rdf:type schema:CreativeWork
    259 sg:pub.10.1038/sj.bjc.6605483 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007615167
    260 https://doi.org/10.1038/sj.bjc.6605483
    261 rdf:type schema:CreativeWork
    262 sg:pub.10.1038/sj.gt.3302756 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017810235
    263 https://doi.org/10.1038/sj.gt.3302756
    264 rdf:type schema:CreativeWork
    265 sg:pub.10.1186/1479-5876-5-32 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001875982
    266 https://doi.org/10.1186/1479-5876-5-32
    267 rdf:type schema:CreativeWork
    268 sg:pub.10.1186/2045-824x-6-18 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021771246
    269 https://doi.org/10.1186/2045-824x-6-18
    270 rdf:type schema:CreativeWork
    271 sg:pub.10.1186/s13046-016-0427-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019155476
    272 https://doi.org/10.1186/s13046-016-0427-7
    273 rdf:type schema:CreativeWork
    274 grid-institutes:None schema:alternateName Medical Oncology, Beatson West of Scotland Cancer Center, Glasgow, UK
    275 schema:name Medical Oncology, Beatson West of Scotland Cancer Center, Glasgow, UK
    276 rdf:type schema:Organization
    277 grid-institutes:grid.32224.35 schema:alternateName Massachusetts General Hospital Cancer Center, Boston, MA, USA
    278 schema:name Massachusetts General Hospital Cancer Center, Boston, MA, USA
    279 rdf:type schema:Organization
    280 grid-institutes:grid.418765.9 schema:alternateName Eisai Co., Ltd, Ibaraki, Japan
    281 Eisai, Co., Ltd, Tokyo, Japan
    282 schema:name Eisai Co., Ltd, Ibaraki, Japan
    283 Eisai, Co., Ltd, Tokyo, Japan
    284 rdf:type schema:Organization
    285 grid-institutes:grid.418767.b schema:alternateName Eisai Inc., Woodcliff Lake, NJ, USA
    286 schema:name Eisai Inc., Woodcliff Lake, NJ, USA
    287 rdf:type schema:Organization
    288 grid-institutes:grid.5072.0 schema:alternateName Department of Medical Oncology, Royal Marsden NHS Foundation Trust, London, UK
    289 schema:name Department of Medical Oncology, Royal Marsden NHS Foundation Trust, London, UK
    290 rdf:type schema:Organization
    291 grid-institutes:grid.51462.34 schema:alternateName Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    292 schema:name Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    293 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...